Influvac Tetra

B/Phuket/3073/2013-like virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the specified B virus strains in individuals for whom vaccination is recommended.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality assurance and regulatory compliance for global influenza vaccination programs through reliable cold‑chain logistics.

Influvac Tetra is a quadrivalent influenza vaccine used to prevent influenza infection caused by specific virus strains. - Prevention of influenza infection caused by influenza virus B/Phuket/3073/2013‑like strain: reduces the risk of illness in vaccinated individuals. - Prevention of influenza infection caused by influenza virus B/Austria/1359417/202 strain: reduces the risk of illness in vaccinated individuals. - Seasonal influenza prevention: provides broader protection against circulating influenza viruses during the flu season.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise. - Headache: mild headache within 24‑48 hours. - Myalgia: muscle aches or soreness. - Fatigue: temporary tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Severe allergic reaction: hives, swelling of face or throat. - High fever: temperature >39°C persisting more than 48 hours. - Seizures: rare convulsive episodes. - Acute respiratory distress: difficulty breathing post‑vaccination.

Before administering Influvac Tetra, consider the following precautions: - Severe allergy: avoid in persons with known hypersensitivity to any vaccine component. - Pregnancy: consult a healthcare provider; vaccination may be given if benefits outweigh potential risks. - Immunocompromised patients: vaccine may be less effective; assess individual benefit. - Age restriction: not recommended for children younger than 6 months. - Acute illness: defer vaccination if the individual has moderate or severe fever or infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with other medicines or vaccines as follows: Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration with live influenza vaccines. - Immunoglobulin therapy: may reduce vaccine efficacy if given concurrently. - Antiviral agents (e.g., oseltamivir) within 48 hours: may interfere with immune response. Moderate Interactions (Monitor Closely): - Other vaccines: can be administered at separate sites, monitor for additive local reactions. - Immunosuppressive drugs: may diminish antibody response; consider serologic testing.